Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 14/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12394906 | 0.90 | MAPK10 (0.39) | MAPK10MAPK8USP30FLT3CHRNA7 | |
| SCHEMBL17310294 | 0.88 | USP30 (0.38) | MAPK10MAPK8USP30FLT3CHRNA7 | |
| SCHEMBL12369463 | 0.84 | CA12 (0.46) | MAPK10MAPK8USP30FLT3 | |
| SCHEMBL2273364 | 0.82 | MAPK10 (0.43) | MAPK10MAPK8USP30 | |
| SCHEMBL12369465 | 0.81 | MAPK10 (0.47) | MAPK10MAPK8 | |
| SCHEMBL2270629 | 0.81 | MAPK10 (0.45) | MAPK10MAPK8 | |
| SCHEMBL2273841 | 0.80 | MAPK10 (0.42) | MAPK10MAPK8 | |
| SCHEMBL2274347 | 0.79 | ADRA1D (0.42) | MAPK10MAPK8FLT3 | |
| SCHEMBL12369467 | 0.79 | MAPK10 (0.49) | MAPK10MAPK8 | |
| SCHEMBL12369449 | 0.78 | MAPK10 (0.44) | MAPK10MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | claimed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | MAPK10 3940/4885MAPK8 3551/4885USP30 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.